

To: lannarone, Lauren B SCC-CSEA <Lauren.lannarone@shell.com>
From: Clegg, Patsy M SCC-CHSE-PC
</O=SHELL/OU=MSXSCC/CN=RECIPIENTS/CN=PH197432>
Cc:
Bcc:
Received Date: 2004-09-15 16:58:59 GMT
Subject: FW: Issues Documents for Shanghai Benzene Study

Lauren,

Apologies for not following up sooner. I am okay with the issues list and matrix. Made a few suggested changes in the 3Q04 update.

Had a call this morning with Nancy, Susan, Sam Smolik, and the 3 regional VPs for Base Chemicals to talk about transition to the base chemicals as sponsors. Have a lot of action items and need to discuss with you. Will call you later.

Haven't forgotten the CAA residual risk - will follow up shortly.

Regards,
Patsy

Patsy Clegg
Product Steward
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 2521 Fax: 3325
Email: patsy.clegg@shell.com
Internet: <http://www.shell.com/chemicals>

-----Original Message-----

From: lannarone, Lauren B SCC-CSEA
Sent: Tuesday, September 14, 2004 5:54 PM
To: Clegg, Patsy M SCC-CHSE-PC
Subject: FW: Issues Documents for Shanghai Benzene Study
Importance: High

Patsy - any thoughts on the info below? If we are going to send Ek Kia a note, perhaps we could send him something to the q3 update below - let me know if you want Mike McGarry to send to him? He is in Beijing starting tonight our time -

Let me know your thoughts - thanks!

Lauren lannarone
Issues Manager
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1- 713-241-7283 7283 Other Tel: 917-362-5456
Email: Lauren.lannarone@shell.com
Internet: <http://www.shell.com/chemicals>

-----Original Message-----

From: lannarone, Lauren B SCC-EXT AFF

Sent: Thursday, September 09, 2004 9:04 PM
To: Clegg, Patsy M SCC-CHSE-PC; Tsai, Shan P SHLOIL-SHS; Cagen, Stuart Z SCC-HSE; Sarah J
SCC-CSEA Colletti (E-mail)
Subject: Issues Documents for Shanghai Benzene Study

Dear all:

As discussed, please find a revised issues matrix and issue plan. I have developed a template that can be used
- I need your help in filling this out if you think it would be helpful.

I am also attaching a draft Q3 update on the study for dissemination to our internal Shell stakeholders - please
review, edit and/or add anything that I missed. I have to confess that I borrowed language from the API
summary note. Hope this is ok - we can try and get the internal summary out in the next week or so, if you
would like -

Best Regards,

Lauren

Lauren Iannarone
Issues Manager
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1- 713-241-7283 7283 Other Tel: 917-362-5456
Email: Lauren.Iannarone@shell.com
Internet: <http://www.shell.com/chemicals>

Attachments:

issueplan_sept04v1.ZIP
q4summary_v1.ZIP
Shanghai_issuesssept2004.ZIP

Shanghai Health Study - Project Update – Q3 2004
September 9, 2004
DRAFT

The objective of this memo is to provide an update on the Shanghai Health Study (SHS). This study, sponsored by the Benzene Health Research Consortium of which Shell Chemicals is a member, is a multi-stakeholder health study in Shanghai, China, which aims to better define the hazards and health risks from exposure to benzene.

The SHS held its second annual meeting in August 2004 in Monterrey, California. The meeting brought together the Principal Investigators (both Chinese and American research team members), the Scientific and Ethics Review Panel members and the industry sponsors. The objective of the meeting was to provide a forum for reviewing the study's progress to date and expectations going forward. The two-day meeting included an open plenary session intended to discuss the progress of the study to date as well as closed meetings of the Scientific and Ethics Review Panel members and the Principal Investigators.

Patsy Clegg, Shell Chemical's Benzene Product Steward and Chair of the Benzene Health Research Consortium Oversight Committee, opened the session emphasizing the participating companies' ongoing commitment to product stewardship; the importance of the industry's commitment to better understanding the potential effects of benzene exposure and the study's role in helping industry effectively manage and minimize risk. Patsy also emphasized the importance of the cooperative and collaborative relationships that have been established among the researchers, the Scientific Review Panel and the Ethics Review Panel.

Participants offered their views on some key accomplishments and milestones including:

- The launch of the start-of-the-art lab Joint Sino-U.S. Clinical and Molecular Laboratory (JCML) at Fudan University in December 2003
- Partnership with 30 Shanghai hospitals that have allied themselves with the JCML
- Since January 2004, the inflow of cases into the JCML has exceeded expectations by two times the original estimate.
- No cases or controls have refused to participate in the study
- Several factories have agreed to participate and formal data collection is underway for 3-4 factories; the PI's conducted preliminary analyses on one factory, a Shanghai rubber factory.
- Preliminary results indicate that the study will indeed make a difference and help bring new clarity to the field.

Some of the key challenges noted at the conference include:

- Efforts to recruit factories and current workers to participate
- Data gathering and measurement of the workplace environments
- Quality control associated with recruiting of participants

In closing, the participants emphasized the importance of accurate exposure assessments to achieving the goals of all three studies; seeking to establish dose-effect relationships between benzene exposure and adverse health consequences. The participants also highlighted the importance of ensuring that the JCML continue to operate, providing diagnostic services and support for research long after the SHS concludes in 2006.

The 2005 meeting would be held in Shanghai the first week of November.

Background on the SHS:

Shell Chemical is participating in a multi-stakeholder health study in Shanghai, China, which aims to better define the hazards and health risks from exposure to benzene. The project participants include a wide range of stakeholders including the Fudan University Medical Center, University of Colorado Health Sciences Center; Applied Health Sciences, Chinese public health agencies, Shanghai hospitals as well as several peer energy and chemical companies. This study, which is part of our commitment to product stewardship, will help clarify previous assumptions regarding benzene health risks and will also help address some recent questions about benzene hazards and exposure. Further, this information will provide the industry with information, which we can use to determine what, if any, improvements are needed in existing protocols. The study will examine past and current exposures in Shanghai-area manufacturing facilities (none are Shell facilities and the benzene not a Shell product). A state-of-the-art clinical and molecular laboratory was built on the Fudan Medical University campus to support the research project and the Shanghai medical community. Chinese technicians have been trained to operate the lab. This facility will remain at Fudan once the project is completed.

For additional information or inquiries, please contact Patsy Clegg at 713-241-2521 or patsy.clegg@shell.com.